Novartis sues Regeneron over eye treatment

22-03-2018

Novartis sues Regeneron over eye treatment

kadmy / iStockphoto.com

Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea (aflibercept) and Zaltrap (ziv-aflibercept).


Novartis, Regeneron, eye disorder, retina disorder, Lucentis, Eylea, Zaltrap, District Court for the Southern District of New York, patented medical techno

LSIPR